Malignant Rhabdoid Tumor of Soft Tissue

Introduction Malignant rhabdoid tumor (MRT) is defined as a high-grade sarcoma derived from an uncertain cell of origin. Its diagnosis is associated with poor prognosis and patient’s life expectancy is greatly reduced. Material and method Here, we describe a unique case of 9-month-old boy who presented with a large MRT arising from the soft tissue of the neck. Following intensive multimodal treatment, the patient benefited from a 25 years’ remission until the discovery of multiple liver metastases. Conclusion MRT of soft tissue needs to be distinguished from other soft tissue neoplasms, as MRT is highly aggressive and is usually associated with a poor outcome. In addition, this is the longest remission time reported in a patient with soft tissue MRT and this might be related to the use of early intensive multimodal treatments.

[1]  J. Biegel,et al.  SWI/SNF chromatin remodeling complexes and cancer , 2014, American journal of medical genetics. Part C, Seminars in medical genetics.

[2]  P. Modena,et al.  Favorable outcome of patients affected by rhabdoid tumors due to rhabdoid tumor predisposition syndrome (RTPS) , 2014, Pediatric blood & cancer.

[3]  O. Witt,et al.  High-dose chemotherapy (HDCT) with auto-SCT in children with atypical teratoid/rhabdoid tumors (AT/RT): a report from the European Rhabdoid Registry (EU-RHAB) , 2014, Bone Marrow Transplantation.

[4]  H. Oka,et al.  Atypical teratoid/rhabdoid tumor with 26-year overall survival: case report. , 2012, Journal of neurosurgery. Pediatrics.

[5]  J. Hornick,et al.  INI1-Deficient Tumors: Diagnostic Features and Molecular Genetics , 2011, The American journal of surgical pathology.

[6]  J. Biegel,et al.  Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors , 2011, Pediatric blood & cancer.

[7]  John Anderson,et al.  Malignant rhabdoid tumors: A familial condition? , 2011, Pediatric blood & cancer.

[8]  N. André,et al.  Frequent hSNF5/INI1 Germline Mutations in Patients with Rhabdoid Tumor , 2011, Clinical Cancer Research.

[9]  C. Rodríguez-Galindo,et al.  Age, stage, and radiotherapy, but not primary tumor site, affects the outcome of patients with malignant rhabdoid tumors , 2010, Pediatric blood & cancer.

[10]  C. Roberts,et al.  The role of SMARCB1/INI1 in the development of rhabdoid tumors , 2009, Cancer biology & therapy.

[11]  O. Delattre,et al.  Extra‐renal non‐cerebral rhabdoid tumours , 2008, Pediatric blood & cancer.

[12]  C. Fletcher,et al.  Myoepithelial Carcinoma of Soft Tissue in Children: An Aggressive Neoplasm Analyzed in a Series of 29 Cases , 2007, The American journal of surgical pathology.

[13]  D. Rakheja,et al.  Absence of expression of SMARCB1/INI1 in malignant rhabdoid tumors of the central nervous system, kidneys and soft tissue: an immunohistochemical study with implications for diagnosis , 2006, Modern Pathology.

[14]  A. Fabre,et al.  Soft-Tissue Extrarenal Rhabdoid Tumor with a Unique Long-Term Survival , 2004, Ultrastructural pathology.

[15]  L. Helman,et al.  Pediatric soft tissue sarcomas , 1994, CA: a cancer journal for clinicians.

[16]  G. Bratthauer,et al.  Epithelioid Variant of Malignant Peripheral Nerve Sheath Tumor (Malignant Epithelioid Schwannoma) , 1991, The American journal of surgical pathology.

[17]  J. Papadimitriou,et al.  Epithelioid Sarcoma: A Diagnostic Problem , 1986, The American Journal of dermatopathology.

[18]  E. Beckwith,et al.  Histopathology and prognosis of Wilms tumor Results from the first national wilms' tumor study , 1978, Cancer.

[19]  J. Biegel,et al.  Loss of INI1 expression defines a unique subset of pediatric undifferentiated soft tissue sarcomas , 2009, Modern Pathology.

[20]  J. Biegel,et al.  Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. , 1999, Cancer research.